阿加曲班抗凝治疗急性脑梗死的疗效观察

发布时间：2018-03-24 20:02

本文选题：脑梗死　切入点：阿加曲班　出处：《临床神经病学杂志》2017年02期

【摘要】：目的观察阿加曲班抗凝治疗发病48 h内的急性脑梗死的疗效。方法收集2014年1月~2015年10月我院神经内科收治的发病48 h内的急性脑梗死患者。根据是否使用阿加曲班治疗分组,使用阿加曲班的患者入试验组,未使用阿加曲班的患者入对照组。在治疗前、后及病程14 d时进行NIHSS评分,病程6个月时进行mRS评分。比较两组疗效。结果本研究共计入组155例患者,试验组107例,对照组48例。两组患者年龄、性别、入院时血压、NIHSS评分等差异均无统计学意义。试验组NIHSS评分改善值明显高于对照组,6个月时mRS评分明显低于对照组(均P0.05)。对照组病程14 d时NIHSS评分明显低于NIHSS评分峰值,试验组病程14 d时NIHSS评分明显低于入院时NIHSS评分和NIHSS评分峰值(均P0.05)。结论发病48 h内的急性脑梗死患者采用阿加曲班抗凝治疗疗效和预后较好。
[Abstract]:Objective to observe the efficacy of Agatripine in the treatment of acute cerebral infarction within 48 hours after onset. Methods patients with acute cerebral infarction within 48 hours of onset were collected from January 2014 to October 2015. Patients with Agatripine were enrolled in the trial group, and those who did not received Agatripine were enrolled in the control group. The NIHSS scores were evaluated before, after treatment and at 14 days after the treatment. After 6 months of disease course, mRS score was used to compare the curative effect between the two groups. Results in this study, there were 155 patients in the study group, 107 patients in the trial group and 48 patients in the control group. There was no significant difference in the scores of blood pressure and NIHSS at admission. The improvement value of NIHSS score in the trial group was significantly higher than that in the control group, and the mRS score at 6 months was significantly lower than that in the control group (all P 0.05). The NIHSS score in the control group was significantly lower than the peak value of NIHSS score at 14 days after the course of disease. The NIHSS score at 14 days after the onset of disease in the trial group was significantly lower than the peak value of NIHSS score and NIHSS score at admission (all P 0.05). Conclusion Agatripine anticoagulant therapy is effective and prognostic in patients with acute cerebral infarction within 48 hours of onset.
【作者单位】：南京医科大学附属苏州医院神经内科;
【分类号】：R743.33

【相似文献】